Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension

doi:10.4254/wjh.v6.i11.825

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6075)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series.

Item

Count

PDF

401

WORD

290

HTML

3103

Figures (1-4)

254

Sum=4048

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

919

Download

1108

Sum=2027

Nov 27, 2014 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Hepatol. Nov 27, 2014; 6(11): 825-829
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.825

Full Size Figure Download Figure

Figure 2 Clinical course and treatment of case 1. Plasma brain natriuretic peptide concentration remarkably decreased from 2212 pg/mL to 46 pg/mL by intravenous dobutamin infusion and subsequent oral ambrisentan-tadalafil combination treatment.

Citation: Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol 2014; 6(11): 825-829
URL: https://www.wjgnet.com/1948-5182/full/v6/i11/825.htm
DOI: https://dx.doi.org/10.4254/wjh.v6.i11.825